Curanex Pharmaceuticals Inc
CURX
$0.31
$0.000.07%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 574.33% | 981.57% | 193.57% | 30.54% | 71.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2,215.20% | 4,153.92% | 919.61% | 30.54% | 71.45% |
| Operating Income | -2,215.20% | -4,153.92% | -919.61% | -30.54% | -71.45% |
| Income Before Tax | -2,189.39% | -2,006.31% | -946.16% | -36.43% | -71.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2,189.39% | -2,006.31% | -946.16% | -36.43% | -71.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2,189.39% | -2,006.31% | -946.16% | -36.43% | -71.57% |
| EBIT | -2,215.20% | -4,153.92% | -919.61% | -30.54% | -71.45% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1,849.12% | -2,908.33% | 1.84% | 86.41% | 95.74% |
| Normalized Basic EPS | -1,830.56% | -6,054.55% | 1.69% | 86.09% | 95.69% |
| EPS Diluted | -1,011.00% | -2,908.33% | 1.84% | 86.41% | 92.52% |
| Normalized Diluted EPS | -1,830.56% | -6,054.55% | 1.69% | 86.09% | 95.69% |
| Average Basic Shares Outstanding | 18.10% | -29.83% | 966.65% | 900.00% | 3,900.00% |
| Average Diluted Shares Outstanding | 18.10% | -29.83% | 966.65% | 900.00% | 3,900.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |